STAA - STAAR Surgical Co Stock Price, Fair Value and News

42.70USD+0.08 (+0.19%)Market Closed

Market Summary

USD42.70+0.08

Market Closed

0.19%

STAA Alerts

Big fall in earnings (Y/Y)

Losses in recent quarter

STAA Stock Price

View Fullscreen

STAA RSI Chart

STAA Valuation

Market Cap

2.1B

Price/Earnings (Trailing)

137.14

Price/Sales (Trailing)

6.43

EV/EBITDA

58.78

Price/Free Cashflow

100.48

STAA Price/Sales (Trailing)

STAA Profitability

EBT Margin

8.20%

Return on Equity

3.89%

Return on Assets

3.11%

Free Cashflow Yield

STAA Fundamentals

STAA Revenue

Revenue (TTM)

326.2M

Rev. Growth (Yr)

5.21%

Rev. Growth (Qtr)

1.42%

STAA Earnings

Earnings (TTM)

15.3M

Earnings Growth (Yr)

-223.21%

Earnings Growth (Qtr)

-143.05%

Breaking Down STAA Revenue

Last 7 days

0.8%

Last 30 days

-7.8%

Last 90 days

38.4%

Trailing 12 Months

-33.2%

How does STAA drawdown profile look like?

STAA Financial Health

Current Ratio

5.84

STAA Investor Care

Shares Dilution (1Y)

1.65%

Diluted EPS (TTM)

0.31

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	326.2M	0	0	0
2023	294.7M	305.9M	310.2M	322.4M
2022	242.9M	261.7M	279.3M	284.4M
2021	179.0M	206.2M	217.5M	230.5M
2020	152.8M	148.3M	156.3M	163.5M
2019	129.4M	135.2M	142.5M	150.2M
2018	97.4M	109.3M	117.6M	124.0M
2017	83.5M	84.5M	87.9M	90.6M
2016	77.5M	79.9M	81.2M	82.4M
2015	73.7M	72.3M	72.8M	77.1M
2014	74.4M	76.3M	77.4M	75.0M
2013	66.3M	68.5M	69.7M	72.2M
2012	63.4M	63.1M	63.7M	63.8M
2011	56.0M	58.7M	60.8M	62.8M
2010	0	52.4M	53.7M	55.0M
2009	0	0	0	51.1M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of STAAR Surgical Co

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 08, 2024	michna magda	sold (taxes)	-68,503	41.02	-1,670	chief clinical, regulatory,
May 08, 2024	foust warren	sold (taxes)	-99,186	41.02	-2,418	chief operating officer
Mar 14, 2024	weisner aimee s	bought	66,692	38.11	1,750	-
Mar 12, 2024	butcher arthur c	acquired	-	-	649	-
Mar 12, 2024	jiang wei	acquired	-	-	1,299	-
Mar 07, 2024	williams patrick f.	acquired	-	-	2,614	chief financial officer
Jan 08, 2024	broadwood partners, l.p.	bought	-	-	-	-
Jan 08, 2024	broadwood partners, l.p.	bought	109,570	27.1079	4,042	-
Jan 05, 2024	broadwood partners, l.p.	bought	4,463,230	28.4765	156,734	-
Jan 05, 2024	broadwood partners, l.p.	bought	-	-	-	-

Which funds bought or sold STAA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-5.9	204,776	1,533,570	-%
May 16, 2024	COMERICA BANK	reduced	-8.86	87,359	828,498	-%
May 16, 2024	Beacon Capital Management, LLC	new	-	957	957	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-56.81	-1,076,320	1,212,560	-%
May 15, 2024	Walleye Capital LLC	reduced	-75.9	-621,467	260,840	-%
May 15, 2024	DARK FOREST CAPITAL MANAGEMENT LP	new	-	309,226	309,226	0.05%
May 15, 2024	CAPITAL FUND MANAGEMENT S.A.	added	229	1,238,030	1,645,500	-%
May 15, 2024	Quarry LP	new	-	1,072	1,072	-%
May 15, 2024	Man Group plc	sold off	-100	-241,003	-	-%
May 15, 2024	Point72 Hong Kong Ltd	sold off	-100	-716,394	-	-%

Are Funds Buying or Selling STAA?

Are funds buying STAA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own STAA

No. of Funds

Unveiling STAAR Surgical Co's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	11.20%	5,468,710	SC 13G/A
Jan 26, 2024	baillie gifford & co	9.11%	4,448,208	SC 13G/A
Jan 22, 2024	blackrock inc.	16.7%	8,159,763	SC 13G/A
Jan 10, 2024	broadwood partners, l.p.	22.1%	0	SC 13D/A
Nov 15, 2023	broadwood partners, l.p.	20.7%	0	SC 13D/A
Oct 10, 2023	broadwood partners, l.p.	19.5%	0	SC 13D/A
Sep 07, 2023	blackrock inc.	17.2%	8,328,302	SC 13G/A
Feb 09, 2023	vanguard group inc	11.01%	5,306,915	SC 13G/A
Jan 23, 2023	blackrock inc.	11.9%	5,738,044	SC 13G/A
Jan 19, 2023	baillie gifford & co	10.87%	5,240,456	SC 13G/A

Recent SEC filings of STAAR Surgical Co

View All Filings

Date Filed	Form Type	Document
May 13, 2024	4	Insider Trading
May 09, 2024	4	Insider Trading
May 09, 2024	4	Insider Trading
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 24, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	DEFA14A	DEFA14A
Apr 04, 2024	8-K	Current Report
Mar 18, 2024	8-K	Current Report

Peers (Alternatives to STAAR Surgical Co)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

STAAR Surgical Co News

Latest updates

STAAR Surgical Co Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	1.4%	77.00	76.00	80.00	92.00	74.00	64.00	76.00	81.00	63.00	59.00	58.00	62.00	51.00	46.00	47.00	35.00	35.00	39.00	39.00	40.00	33.00
Gross Profit	0.5%	61.00	61.00	64.00	71.00	58.00	50.00	60.00	64.00	49.00	45.00	45.00	49.00	39.00	34.00	35.00	24.00	25.00	29.00	29.00	30.00	24.00
S&GA Expenses	25.8%	63.00	50.00	57.00	62.00	55.00	49.00	47.00	47.00	37.00	38.00	37.00	39.00	32.00	30.00	30.00	25.00	26.00	26.00	26.00	25.00	23.00
R&D Expenses	23.1%	13.00	11.00	11.00	12.00	10.00	10.00	10.00	9.00	8.00	9.00	8.00	8.00	8.00	9.00	9.00	7.00	7.00	7.00	6.00	6.00	6.00
EBITDA Margin	-18.8%	0.10*	0.12*	0.10*	0.12*	0.15*	0.18*	0.18*	0.17*	0.17*	0.15*	0.15*	0.15*	-	-	-	-	-	-	-	-	-
Income Taxes	-81.1%	1.00	6.00	2.00	2.00	2.00	-0.78	2.00	2.00	2.00	-0.96	1.00	2.00	1.00	1.00	1.00	1.00	-1.16	-3.40	1.00	1.00	0.00
Earnings Before Taxes	-116.1%	-2.21	14.00	7.00	8.00	5.00	6.00	13.00	15.00	12.00	7.00	7.00	11.00	6.00	5.00	5.00	-0.62	-1.29	3.00	3.00	5.00	2.00
EBT Margin	-21.5%	0.08*	0.10*	0.08*	0.10*	0.13*	0.16*	0.17*	0.16*	0.15*	0.14*	0.13*	0.13*	-	-	-	-	-	-	-	-	-
Net Income	-143.1%	-3.34	8.00	5.00	6.00	3.00	7.00	10.00	13.00	10.00	5.00	6.00	9.00	5.00	3.00	4.00	-1.17	-0.13	6.00	2.00	4.00	1.00
Net Income Margin	-29.2%	0.05*	0.07*	0.07*	0.08*	0.11*	0.14*	0.14*	0.13*	0.12*	0.11*	0.11*	0.10*	-	-	-	-	-	-	-	-	-
Free Cashflow	-42.9%	16.00	29.00	-15.16	-9.32	-7.99	-1.05	18.00	8.00	-7.15	4.00	19.00	3.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	0.8%	493	489	472	441	419	419	395	376	351	346	325	294	266	257	235	218	207	208	193	186	177
Current Assets	0.1%	366	365	347	328	313	312	297	296	274	271	264	248	224	216	196	183	172	175	165	159	153
Cash Equivalents	22.4%	224	183	127	95.00	90.00	86.00	129	202	193	200	196	173	162	152	128	116	111	120	112	103	102
Net PPE	8.2%	72.00	67.00	63.00	56.00	53.00	51.00	48.00	43.00	40.00	36.00	32.00	29.00	26.00	24.00	23.00	21.00	20.00	17.00	15.00	13.00	11.00
Goodwill	0%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Liabilities	-2.9%	100	103	93.00	87.00	80.00	83.00	75.00	77.00	75.00	87.00	75.00	60.00	52.00	60.00	48.00	43.00	42.00	48.00	43.00	42.00	40.00
Current Liabilities	-3.6%	63.00	65.00	57.00	54.00	47.00	52.00	45.00	47.00	41.00	49.00	47.00	42.00	36.00	41.00	34.00	32.00	30.00	34.00	30.00	29.00	28.00
Shareholder's Equity	1.8%	393	386	379	358	339	336	323	302	276	262	249	235	214	197	186	175	165	160	149	144	137
Retained Earnings	-7.0%	-50.71	-47.37	-55.12	-63.86	-69.92	-68.71	-78.49	-88.75	-101	-108	-116	-122	-130	-135	-139	-143	-141	-141	-148	-150	-154
Additional Paid-In Capital	2.5%	448	437	436	420	409	404	398	387	379	374	369	360	348	338	328	320	309	304	300	296	293
Shares Outstanding	0.6%	49.00	49.00	49.00	48.00	48.00	48.00	48.00	48.00	48.00	47.00	47.00	47.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	2,567	-	-	-	3,467	-	-	-	6,859	-	-	-	2,821	-	-	-	1,308	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-32.2%	21,680	31,969	-5,975	-6,306	-5,094	2,970	24,109	13,246	-4,610	8,498	22,316	6,382	6,766	19,550	9,589	-17.00	-8,171	9,793	11,794	3,477	731
Share Based Compensation	3383.0%	6,339	182	8,846	8,423	6,065	4,996	5,727	5,754	3,894	3,620	3,663	3,992	3,330	3,181	3,126	2,918	2,921	2,769	2,558	2,579	2,641
Cashflow From Investing	-27.7%	16,187	22,402	31,840	10,172	9,933	-46,717	-101,849	-5,271	-2,539	-4,689	-3,273	-3,524	-2,159	-2,145	-2,049	-2,025	-2,185	-2,979	-2,568	-2,398	-2,233
Cashflow From Financing	1005.2%	4,056	367	7,107	1,302	-1,361	202	4,994	2,207	894	-216	4,176	7,833	6,000	6,550	4,317	7,440	1,264	828	-111	-328	-240

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

STAA Income Statement

2024-03-29

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 29, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net sales	$ 77,356	$ 73,528
Cost of sales	16,321	15,966
Gross profit	61,035	57,562
Selling, general and administrative expenses:
General and administrative	23,228	18,098
Selling and marketing	26,708	26,354
Research and development	13,380	10,310
Total selling, general and administrative expenses	63,316	54,762
Operating income (loss)	(2,281)	2,800
Other income (expense), net:
Interest income, net	1,529	1,822
Gain (loss) on foreign currency transactions	(2,297)	34
Royalty income	508
Other income, net	330	63
Total other income, net	70	1,919
Income (loss) before income taxes	(2,211)	4,719
Provision for income taxes	1,128	2,009
Net income (loss)	$ (3,339)	$ 2,710
Net income (loss) per share:
Basic	$ (0.07)	$ 0.06
Diluted	$ (0.07)	$ 0.05
Weighted average shares outstanding:
Basic	48,907	48,247
Diluted	48,907	49,500

STAA Balance Sheet

2024-03-29

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 29, 2024	Dec. 29, 2023
Current assets:
Cash and cash equivalents	$ 224,024	$ 183,038
Investments available for sale	21,125	37,688
Accounts receivable trade, net of allowance for credit losses of $187 and $191, respectively	64,604	94,704
Inventories, net	38,581	35,130
Prepayments, deposits and other current assets	17,381	14,709
Total current assets	365,715	365,269
Investments available for sale	6,963	11,703
Property, plant and equipment, net	72,337	66,835
Finance lease right-of-use assets, net	146	183
Operating lease right-of-use assets, net	34,600	34,387
Goodwill	1,786	1,786
Deferred income taxes	5,125	5,190
Other assets	5,863	3,339
Total assets	492,535	488,692
Current liabilities:
Accounts payable	16,560	13,557
Obligations under finance leases	166	165
Obligations under operating leases	4,403	4,202
Allowance for sales returns	6,284	6,174
Other current liabilities	35,261	40,938
Total current liabilities	62,674	65,036
Obligations under finance leases		42
Obligations under operating leases	31,126	31,425
Deferred income taxes	1,074	1,077
Asset retirement obligations	96	103
Pension liability	4,777	5,055
Total liabilities	99,747	102,738
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.01 par value; 60,000 shares authorized: 49,120 and 48,839 shares issued and outstanding at March 29, 2024 and December 29, 2023, respectively	491	488
Additional paid-in capital	447,716	436,947
Accumulated other comprehensive income (loss)	(4,712)	(4,113)
Accumulated deficit	(50,707)	(47,368)
Total stockholders’ equity	392,788	385,954
Total liabilities and stockholders’ equity	$ 492,535	$ 488,692

About STAAR Surgical Co

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

CEO	Mr. Thomas G. Frinzi
WEBSITE	staar.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	882

STAAR Surgical Co Frequently Asked Questions

What is the ticker symbol for STAAR Surgical Co? What does STAA stand for in stocks?

STAA is the stock ticker symbol of STAAR Surgical Co. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of STAAR Surgical Co (STAA)?

As of Fri May 17 2024, market cap of STAAR Surgical Co is 2.1 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of STAA stock?

You can check STAA's fair value in chart for subscribers.

What is the fair value of STAA stock?

You can check STAA's fair value in chart for subscribers. The fair value of STAAR Surgical Co is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of STAAR Surgical Co is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for STAA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is STAAR Surgical Co a good stock to buy?

The fair value guage provides a quick view whether STAA is over valued or under valued. Whether STAAR Surgical Co is cheap or expensive depends on the assumptions which impact STAAR Surgical Co's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for STAA.

What is STAAR Surgical Co's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, STAA's PE ratio (Price to Earnings) is 137.14 and Price to Sales (PS) ratio is 6.43. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. STAA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on STAAR Surgical Co's stock?

In the past 10 years, STAAR Surgical Co has provided 0.114 (multiply by 100 for percentage) rate of return.